An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for Perfluoroalkyl and Polyfluoroalkyl Substances
Maine Legislature, Session 131, LD 0132
Committee Amendment CA_A_S654 (Senate)
Amends: 24-A MRSA §4320-W

COMMTTTEE AMENDMENT "A"" to S.P. 71, L.D. 13 2, "An Act to Require Health
Insurance Carriers to Provide Coverage for Blood Testing for Perfluoroalkyl and
Polyfluoroalkyl Substances"
Amend the bill by striking out everything after the enacting clause and inserting the
followmg:
'See. 1. 24-A MRSA §4320-W is enacted to read:
S4320-W. Coveraee for blood testing for PFAS
1. Definition. As used in this section, unless the context otherwise indicates.
"perfluoroalkvl and polvfluoroalkvl substances" or "PFAS" means any member of the class
of fluorinated organic chemicalsj?Qntammg at least one fully fluorinated carbon atom.
2. Required coverage. A carrier offering a health plan in this State shall provide
coverage for blood testing for uerfluoroalkvl and oolvfluoroalkvl substances that is
recommended by a provider as medically necessary health care for an enrollee. For the
purposes of this subsection, blood testing for PFAS isiiresumed to be medically necessary
health care for an enrollee if a provider determines that the enrollee meets clinical
guidelines for blood testing for PFAS established by the National Academies of Sciences.
Engineering, and Medicine, its successor organization or a comparable organization,
3. Cost sharing prohibited. A health plan may not impose any deductible.
cQBayment, cpinsurance or other cost-sharine requirement for the costs of blood testing
reauired to be covered under subsection 2. This subsection does not apply to a health plan
offered for use with a health savmes account unless the federal Internal Revenue Service
determines that the reauirements^ inthis subsection are permissible in a high deductible
health plan as defmed in the federal Internal Revenue Code. Section 223(c)(2).
Sec. 2. Application. This Act applies to all policies, contracts and certificates
executed, delivered, issued for delivery, continued or renewed in this State on or after
January 1, 2025. For purposes of this Act, all contracts are deemed to be renewed no later
5 than the next yearly anniversary of the contract date.
COMMITTEE AMENDMENT
COMMITTEE AMENDMENT " ft " to S.P. 71, L.D. 132 (cy (fiS^
Sec. 3. Appropriations and allocations. The following appropriations and
allocations are made.
^U^ 3 ADMINISTRATIVE AND FINANCIAL SERVICES, DEPARTMENT OF
State Benefit Mandate Defrayal Z373
Initiative: Provides ongoing funding for the cost of the benefit mandate providing coverage
of blood testing for perfluoroalkyl and polyfluoroalkyl substances, beginning January 1,
2025.
GENERAL FUND 2023-24 2024-25
AllOther $0 $90,000
GENERAL FUND TOTAL $0 $90,000
Amend the bill by relettering or renumbering any nonconsecutive Part letter or section
number to read consecutively.
SUMMARY
This amendment is the majority report of the committee and replaces the bill. The
amendment requires carriers offering health plans in this State to provide coverage for
blood testing for perfluoroalkyl and polyfluoroalkyl substances, or PFAS, recommended
by a provider as medically necessary health care in accordance with clinical guidelines
established by the National Academies of Sciences, Engineering, and Medicine. The
requirements of the amendment apply to health plans issued or renewed on or after January
1, 2025. The amendment also adds an appropriation to provide funding for the costs of the
benefit mandate defrayal required by federal law.
FISCAL NOTE REQUIRED
(See attached)
COMMITTEE AMENDMENT
Revised: 03/28/24 ^2S^
LD 132 LR 143(02)
An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for
Perfluoroalkyl and Polyfluoroalkyl Substances
Fiscal Note for Bill as Amended by Committee Amendment '^(^(^L\
Committee: Health Coverage, Insurance and Financial Services
Fiscal Note Required: Yes
Fiscal Note
FY 2023-24
$0
$0
$0
$0
FY 2024-25
$90,000
$0
$90,000
$0
Projections
FY 2025-26
$223,343
$15,996
$223,343
$15,996
Projections
FY 2026-27
$223,343
$15,996
$223,343
$15,996
Net Cost (Savings)
General Fund
Highway Fund
Appropriations/Allocations
General Fund
Highway Fund
Fiscal Detail and Notes
This bill requires carriers offering health plans in this State to provide coverage for blood testing for perfluoroalkyl
and polyfluoroalkyl substances. The requirements of the bill apply to health plans issued or renewed on or after
January 1, 2025. The bill includes General Fund appropriations to the Department of Administrative and Financial
Services of $90,000 for the estimated cost to reimburse the insurance carriers, for 6 months of the State's defrayal cost
of this new mandate. The mandate will go into effect on all health insurance plans on the marketplace beginning
January 1, 2025 and is estimated to cost $180,000 annually, thereafter.
The State Employee Health Plan's first impacted plan year will be SPY 2026 and is estimated to cost $96,000 annually
thereafter. The costs are split across the General Fund ($43,343), Highway Funds ($15,996) and all other funds
($36,661).
LR0143(02) - Fiscal Note - Page 1 of 1